Cite
[Use of orally disintegrating olanzapine tablet for patients with cancerous peritonitis and postoperative gastric cancer receiving home palliative care].
MLA
Murakami, Nozomu, et al. “[Use of Orally Disintegrating Olanzapine Tablet for Patients with Cancerous Peritonitis and Postoperative Gastric Cancer Receiving Home Palliative Care].” Gan to Kagaku Ryoho. Cancer & Chemotherapy, vol. 39, no. 4, Apr. 2012, pp. 649–52. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=22504695&authtype=sso&custid=ns315887.
APA
Murakami, N., Tanabe, K., Yamatani, K., Kitazawa, H., Fujikawa, Y., Amemiya, Y., Shimada, M., & Kadoya, S. (2012). [Use of orally disintegrating olanzapine tablet for patients with cancerous peritonitis and postoperative gastric cancer receiving home palliative care]. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 39(4), 649–652.
Chicago
Murakami, Nozomu, Kouichi Tanabe, Kaori Yamatani, Hidenori Kitazawa, Yasunaga Fujikawa, Yoko Amemiya, Masanari Shimada, and Shinichi Kadoya. 2012. “[Use of Orally Disintegrating Olanzapine Tablet for Patients with Cancerous Peritonitis and Postoperative Gastric Cancer Receiving Home Palliative Care].” Gan to Kagaku Ryoho. Cancer & Chemotherapy 39 (4): 649–52. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=22504695&authtype=sso&custid=ns315887.